Clinical Trials

Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement, Breast Neoplasms

NCT02096588 2024-07-09

Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin

34 enrolled 11 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06404463 2024-05-08

QUEEN-Neo

76 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06371807 2024-04-17

KEYPARTNER

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00712881 2024-02-23

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

126 enrolled 16 charts

Breast Neoplasms

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

17 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT00679029 2023-12-11

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

15 enrolled 9 charts

Phase 2 Active not recruiting

Breast Neoplasms

NCT04172259 2023-10-16

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

156 enrolled

Breast Neoplasms

NCT00591851 2023-09-25

Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

70 enrolled 6 charts

Breast Neoplasms

NCT00665457 2023-09-13

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

3 enrolled 6 charts

Breast Neoplasms

NCT03329378 2023-08-22

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

7 enrolled 10 charts

Locally Advanced Breast Cancer

NCT00146562 2023-08-02

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

135 enrolled

Breast Neoplasms

NCT05872412 2023-05-25

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

Phase 2 Unknown

82 enrolled

Triple Negative Breast Neoplasms

NCT01147016 2023-04-27

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

8 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00128856 2023-03-06

Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients

46 enrolled

Breast Neoplasms, Disease

NCT03412643 2023-03-06

FB-12

Phase 2 Unknown

64 enrolled

Breast Neoplasms

NCT02067416 2023-02-02

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT02978495 2022-12-28

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

154 enrolled

BreastGynecologic

BRCA1 Hereditary Breast and Ovarian Cancer Syndrome

NCT01779050 2022-11-01

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

7 enrolled 8 charts

Breast Neoplasms

NCT04170465 2022-09-10

METNEO

70 enrolled

Breast Cancer Female

NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

122 enrolled 22 charts